Biotech Stocks Fluctuate Post-Market: Delcath Gains from Buyback, BioVie and Cassava Recover
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 21 2025
0mins
Should l Buy SAVA?
Source: NASDAQ.COM
Delcath Systems' Buyback Announcement: Delcath Systems saw a 4.02% increase in after-hours trading to $8.52 following the announcement of a $25 million share repurchase program, indicating confidence in its long-term outlook.
BioVie Inc. Gains Despite No News: BioVie Inc. rose 13.39% to $1.44 in extended trading, rebounding from a decline during the regular session, with the increase attributed to speculative trading rather than new company-specific news.
Cassava Sciences' After-Hours Rally: Cassava Sciences advanced 9.17% to $2.87 after hours, recovering from a regular session drop, as investors reacted to its recent Q3 results showing a reduced net loss and significant cash reserves.
Enlivex Therapeutics' Modest Increase: Enlivex Therapeutics experienced a 4.24% rise to $0.95 in after-hours trading, despite no new developments reported on Thursday.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SAVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SAVA
About SAVA
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cassava Sciences Concludes DOJ Investigation into Research Misconduct
- DOJ Investigation Closure: Cassava Sciences announced that the U.S. Department of Justice has closed its investigation into research misconduct related to its drug Simufilam, indicating full cooperation during the probe, although the company's stock fell 2% at the time of the announcement.
- SEC Settlement Details: In September 2024, Cassava reached a settlement with the U.S. Securities and Exchange Commission, paying a monetary penalty without admitting or denying the allegations, which involved misleading statements about its Alzheimer's treatment, highlighting the company's vulnerability under regulatory scrutiny.
- New Drug Development Focus: Cassava has shifted its focus from developing Simufilam for Alzheimer's to treating tuberous sclerosis complex-related epilepsy, reflecting a strategic pivot in response to the drug's failure to demonstrate clinical benefits in late-stage trials.
- Market Sentiment Shift: On Stocktwits, retail sentiment around SAVA stock rose from 'neutral' to 'bullish' over the past 24 hours, despite a 25% decline in stock price over the past year, indicating cautious optimism among investors regarding the company's future.
See More
Cassava Sciences Investigation Closed by DOJ
- Investigation Conclusion: The U.S. Department of Justice closed its investigation into Cassava Sciences (SAVA) on October 23, marking a significant legal victory for the company amid allegations of research misconduct related to its Alzheimer's drug candidate, simufilam.
- Background of Allegations: In July 2022, Reuters reported that the DOJ had opened a criminal investigation into whether Cassava manipulated research results for improper gain, but the closure of this investigation provides an opportunity for the company to restore its reputation.
- Settlement Agreement: In 2024, Cassava agreed to pay $40 million to resolve allegations from the SEC regarding misleading claims about Phase 2b trial data for simufilam, demonstrating the company's proactive stance on compliance.
- Full Cooperation: Cassava stated that it fully cooperated with both the DOJ and SEC investigations, and the outcomes not only conclude the investigations but may also pave the way for future business development.
See More
Cassava Technologies and AXON Networks Form Strategic Partnership
- Strategic Partnership Announcement: Cassava Technologies and AXON Networks unveiled their strategic partnership at the Counder Conference in Cape Town, aiming to co-develop Africa's first end-to-end Operator-as-a-Service (OaaS) platform to drive digital transformation through AI-driven network solutions.
- Infrastructure Enhancement: The OaaS platform will leverage Cassava's extensive 110,000 km fiber network to deliver secure, high-speed data infrastructure, significantly enhancing the agility and intelligence of mobile network operators and ISPs, thereby fostering economic growth and innovation.
- AI-Driven Digital Twin Technology: AXON's Digital Twin technology will transform networks into self-learning, self-optimizing systems, reducing operational complexity, accelerating service delivery, and ensuring resilient connectivity at scale, thus providing customers with more efficient service experiences.
- Market Potential Unleashed: This collaboration will not only provide a robust digital foundation for African businesses but also promote widespread AI adoption, helping enterprises gain competitive advantages in the global market and showcasing Africa's immense potential in the digital economy.
See More
Cassava Sciences Faces Shareholder Rights Investigation by Halper Sadeh LLC
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Cassava Sciences, Inc. breached their fiduciary duties to shareholders, potentially impacting corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of Cassava stock may have the opportunity to seek corporate governance reforms, return of funds, or court-approved financial incentive awards, which could directly affect shareholder financial interests and company transparency.
- Importance of Participation: Shareholder involvement can help improve company policies and oversight mechanisms, thereby enhancing management efficiency and transparency, ultimately increasing shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide who have fallen victim to securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its capability in protecting investor rights.
See More
Cassava Sciences Inc. Settles Securities Class Action for $31.25 Million
- Settlement Agreement: Cassava Sciences Inc. has reached a definitive agreement to settle a consolidated securities class action from 2021 by agreeing to pay $31.25 million to resolve all claims related to investors who purchased its common stock or options between September 14, 2020, and October 12, 2023, although the settlement does not include any admission of wrongdoing.
- Financial Implications: The company has fully reserved the $31.25 million settlement amount as a loss contingency in Q2 2025, which will directly impact its future financial condition and potentially affect investor confidence.
- Management Confidence: CEO Rick Barry stated that with this settlement, the company can focus its attention and resources on the continued development of simufilam as a potential treatment for TSC-related epilepsy, indicating a positive outlook during the transition.
- Stock Price Movement: Following the settlement announcement, Cassava's shares fell 1.26% to $2.35 in premarket trading, reflecting market caution regarding the settlement and the company's future developments.
See More
Cassava Sciences Settles $31.25 Million Securities Class Action Litigation
- Settlement Agreement: Cassava Sciences has reached a definitive agreement to pay $31.25 million to resolve a securities class action lawsuit that has been ongoing since 2021, allowing the company to focus on the development of simufilam and enhance its competitive position in CNS disorder treatments.
- Legal Risk Mitigation: The settlement will release all claims related to the litigation without admitting any wrongdoing, which helps to reduce future legal risks and improve investor confidence in the company's operations.
- Financial Provisioning: Cassava fully reserved a loss contingency of $31.25 million in Q2 2025 to address the settlement, ensuring financial transparency and protecting shareholder interests amid ongoing litigation.
- R&D Focus: By resolving this legacy litigation, Cassava can redirect resources towards clinical research for simufilam, with plans for a Phase 2 proof-of-concept study targeting TSC-related epilepsy, further driving innovation in the biotechnology sector.
See More
Cassava Sciences Concludes DOJ Investigation into Research Misconduct
- DOJ Investigation Closure: Cassava Sciences announced that the U.S. Department of Justice has closed its investigation into research misconduct related to its drug Simufilam, indicating full cooperation during the probe, although the company's stock fell 2% at the time of the announcement.
- SEC Settlement Details: In September 2024, Cassava reached a settlement with the U.S. Securities and Exchange Commission, paying a monetary penalty without admitting or denying the allegations, which involved misleading statements about its Alzheimer's treatment, highlighting the company's vulnerability under regulatory scrutiny.
- New Drug Development Focus: Cassava has shifted its focus from developing Simufilam for Alzheimer's to treating tuberous sclerosis complex-related epilepsy, reflecting a strategic pivot in response to the drug's failure to demonstrate clinical benefits in late-stage trials.
- Market Sentiment Shift: On Stocktwits, retail sentiment around SAVA stock rose from 'neutral' to 'bullish' over the past 24 hours, despite a 25% decline in stock price over the past year, indicating cautious optimism among investors regarding the company's future.
See More
Cassava Sciences Investigation Closed by DOJ
- Investigation Conclusion: The U.S. Department of Justice closed its investigation into Cassava Sciences (SAVA) on October 23, marking a significant legal victory for the company amid allegations of research misconduct related to its Alzheimer's drug candidate, simufilam.
- Background of Allegations: In July 2022, Reuters reported that the DOJ had opened a criminal investigation into whether Cassava manipulated research results for improper gain, but the closure of this investigation provides an opportunity for the company to restore its reputation.
- Settlement Agreement: In 2024, Cassava agreed to pay $40 million to resolve allegations from the SEC regarding misleading claims about Phase 2b trial data for simufilam, demonstrating the company's proactive stance on compliance.
- Full Cooperation: Cassava stated that it fully cooperated with both the DOJ and SEC investigations, and the outcomes not only conclude the investigations but may also pave the way for future business development.
See More
Cassava Technologies and AXON Networks Form Strategic Partnership
- Strategic Partnership Announcement: Cassava Technologies and AXON Networks unveiled their strategic partnership at the Counder Conference in Cape Town, aiming to co-develop Africa's first end-to-end Operator-as-a-Service (OaaS) platform to drive digital transformation through AI-driven network solutions.
- Infrastructure Enhancement: The OaaS platform will leverage Cassava's extensive 110,000 km fiber network to deliver secure, high-speed data infrastructure, significantly enhancing the agility and intelligence of mobile network operators and ISPs, thereby fostering economic growth and innovation.
- AI-Driven Digital Twin Technology: AXON's Digital Twin technology will transform networks into self-learning, self-optimizing systems, reducing operational complexity, accelerating service delivery, and ensuring resilient connectivity at scale, thus providing customers with more efficient service experiences.
- Market Potential Unleashed: This collaboration will not only provide a robust digital foundation for African businesses but also promote widespread AI adoption, helping enterprises gain competitive advantages in the global market and showcasing Africa's immense potential in the digital economy.
See More
Cassava Sciences Faces Shareholder Rights Investigation by Halper Sadeh LLC
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Cassava Sciences, Inc. breached their fiduciary duties to shareholders, potentially impacting corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of Cassava stock may have the opportunity to seek corporate governance reforms, return of funds, or court-approved financial incentive awards, which could directly affect shareholder financial interests and company transparency.
- Importance of Participation: Shareholder involvement can help improve company policies and oversight mechanisms, thereby enhancing management efficiency and transparency, ultimately increasing shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide who have fallen victim to securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its capability in protecting investor rights.
See More
Cassava Sciences Inc. Settles Securities Class Action for $31.25 Million
- Settlement Agreement: Cassava Sciences Inc. has reached a definitive agreement to settle a consolidated securities class action from 2021 by agreeing to pay $31.25 million to resolve all claims related to investors who purchased its common stock or options between September 14, 2020, and October 12, 2023, although the settlement does not include any admission of wrongdoing.
- Financial Implications: The company has fully reserved the $31.25 million settlement amount as a loss contingency in Q2 2025, which will directly impact its future financial condition and potentially affect investor confidence.
- Management Confidence: CEO Rick Barry stated that with this settlement, the company can focus its attention and resources on the continued development of simufilam as a potential treatment for TSC-related epilepsy, indicating a positive outlook during the transition.
- Stock Price Movement: Following the settlement announcement, Cassava's shares fell 1.26% to $2.35 in premarket trading, reflecting market caution regarding the settlement and the company's future developments.
See More
Cassava Sciences Settles $31.25 Million Securities Class Action Litigation
- Settlement Agreement: Cassava Sciences has reached a definitive agreement to pay $31.25 million to resolve a securities class action lawsuit that has been ongoing since 2021, allowing the company to focus on the development of simufilam and enhance its competitive position in CNS disorder treatments.
- Legal Risk Mitigation: The settlement will release all claims related to the litigation without admitting any wrongdoing, which helps to reduce future legal risks and improve investor confidence in the company's operations.
- Financial Provisioning: Cassava fully reserved a loss contingency of $31.25 million in Q2 2025 to address the settlement, ensuring financial transparency and protecting shareholder interests amid ongoing litigation.
- R&D Focus: By resolving this legacy litigation, Cassava can redirect resources towards clinical research for simufilam, with plans for a Phase 2 proof-of-concept study targeting TSC-related epilepsy, further driving innovation in the biotechnology sector.
See More
